• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Is BEER the answer?-non-immunotherapeutic targeted maintenance treatment of chemotherapy-responsive advanced biliary tract cancers.

作者信息

Mahmood Umair, Munster Alex B, Khan Khurum

机构信息

Department of Gastrointestinal Oncology, University College Hospital NHS Foundation Trust (UCLH), London, UK.

Department of Cancer Services, Whittington Health NHS Trust, London, UK.

出版信息

Transl Gastroenterol Hepatol. 2025 Jun 13;10:40. doi: 10.21037/tgh-24-158. eCollection 2025.

DOI:10.21037/tgh-24-158
PMID:40755738
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12314684/
Abstract
摘要

相似文献

1
Is BEER the answer?-non-immunotherapeutic targeted maintenance treatment of chemotherapy-responsive advanced biliary tract cancers.啤酒是答案吗？——化疗敏感的晚期胆管癌的非免疫治疗靶向维持治疗
Transl Gastroenterol Hepatol. 2025 Jun 13;10:40. doi: 10.21037/tgh-24-158. eCollection 2025.
2
Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial.贝伐珠单抗联合厄洛替尼作为化疗敏感晚期胆囊癌和胆管癌的维持治疗（BEER BTC）：一项多中心、开放标签、随机、II 期临床试验。
J Clin Oncol. 2024 Sep 20;42(27):3218-3227. doi: 10.1200/JCO.23.02420. Epub 2024 Aug 5.
3
Clinical outcomes for previously treated patients with advanced biliary tract cancer: a meta-analysis.既往接受过治疗的晚期胆管癌患者的临床结局：一项荟萃分析。
Future Oncol. 2024 Apr;20(13):863-876. doi: 10.2217/fon-2023-0006. Epub 2024 Feb 14.
4
Targeting PD-1/PD-L1 in biliary tract cancer: role and available data.靶向程序性死亡蛋白1/程序性死亡蛋白配体1在胆管癌中的作用及现有数据
Immunotherapy. 2023 May;15(7):517-530. doi: 10.2217/imt-2022-0190. Epub 2023 Apr 3.
5
ABC-12: exploring the microbiome in patients with advanced biliary tract cancer in a first-line study of durvalumab (MEDI4736) in combination with cisplatin/gemcitabine.ABC-12：在度伐利尤单抗（MEDI4736）联合顺铂/吉西他滨用于晚期胆管癌患者的一线研究中探索微生物组。
Future Oncol. 2025 Jul 29:1-9. doi: 10.1080/14796694.2025.2539018.
6
Postoperative adjuvant chemotherapy and chemoimmunotherapy after radical resection for biliary tract cancer: a retrospective study.胆管癌根治性切除术后的术后辅助化疗和化疗免疫治疗：一项回顾性研究。
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf163.
7
Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) in patients with unresectable biliary tract cancer treated with gemcitabine, cisplatin, and durvalumab.中性粒细胞与淋巴细胞比值（NLR）对接受吉西他滨、顺铂和度伐利尤单抗治疗的不可切除胆管癌患者的预后影响
World J Surg Oncol. 2025 Jul 1;23(1):258. doi: 10.1186/s12957-025-03834-x.
8
Chemoradiation of locally advanced biliary cancer: A PRISMA-compliant systematic review.局部晚期胆管癌的放化疗：一项遵循PRISMA标准的系统评价
Cancer Med. 2024 Dec;13(23):e70196. doi: 10.1002/cam4.70196.
9
Associations between reproductive factors and biliary tract cancers in women from the Biliary Tract Cancers Pooling Project.女性生殖因素与胆道癌的关系：来自胆道癌汇集项目的研究。
J Hepatol. 2020 Oct;73(4):863-872. doi: 10.1016/j.jhep.2020.04.046. Epub 2020 May 11.
10
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study.度伐利尤单抗治疗晚期胆管癌患者达到维持治疗的相关因素：一项多中心跨国研究的真实世界结果
Int J Cancer. 2025 Sep 15;157(6):1246-1259. doi: 10.1002/ijc.35481. Epub 2025 May 19.

本文引用的文献

1
Optimizing outcomes and personalizing care with targeted agents in advanced cholangiocarcinoma.用靶向药物优化晚期胆管癌的治疗效果和实行个体化治疗。
Cancer Treat Rev. 2024 Dec;131:102851. doi: 10.1016/j.ctrv.2024.102851. Epub 2024 Nov 5.
2
Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial.贝伐珠单抗联合厄洛替尼作为化疗敏感晚期胆囊癌和胆管癌的维持治疗（BEER BTC）：一项多中心、开放标签、随机、II 期临床试验。
J Clin Oncol. 2024 Sep 20;42(27):3218-3227. doi: 10.1200/JCO.23.02420. Epub 2024 Aug 5.
3
Comprehensive Examination of Cholangiocarcinoma Patients Treated with Novel Targeted Therapies after Extended Molecular Profiling on Liquid Biopsies.
对经液体活检进行扩展分子谱分析后接受新型靶向治疗的胆管癌患者的综合检查
Cancers (Basel). 2024 Feb 6;16(4):697. doi: 10.3390/cancers16040697.
4
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.度伐利尤单抗联合吉西他滨和顺铂治疗晚期胆道癌。
NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.
5
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.帕博利珠单抗联合吉西他滨和顺铂与单纯吉西他滨和顺铂治疗晚期胆道癌患者的比较（KEYNOTE-966）：一项随机、双盲、安慰剂对照、3 期临床试验。
Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.
6
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma.基于液体活检的蛋白生物标志物用于胆管癌的风险预测、早期诊断和预后评估。
J Hepatol. 2023 Jul;79(1):93-108. doi: 10.1016/j.jhep.2023.02.027. Epub 2023 Mar 1.
7
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.胆道癌：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Feb;34(2):127-140. doi: 10.1016/j.annonc.2022.10.506. Epub 2022 Nov 10.
8
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial.循环肿瘤 DNA 指导转移性结直肠癌重新使用 panitumumab：2 期 CHRONOS 试验。
Nat Med. 2022 Aug;28(8):1612-1618. doi: 10.1038/s41591-022-01886-0. Epub 2022 Aug 1.
9
Precision Medicine in Biliary Tract Cancer.胆管癌的精准医学
J Clin Oncol. 2022 Aug 20;40(24):2716-2734. doi: 10.1200/JCO.21.02576. Epub 2022 Jul 15.
10
Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.晚期胆管癌二线FOLFOX化疗与积极症状控制的对比研究（ABC-06）：一项3期、开放标签、随机对照试验
Lancet Oncol. 2021 May;22(5):690-701. doi: 10.1016/S1470-2045(21)00027-9. Epub 2021 Mar 30.